Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer

被引:81
作者
Rennstam, Karin [1 ]
McMichael, Nicole [1 ]
Berglund, Pontus [1 ]
Honeth, Gabriella [1 ]
Hegardt, Cecilia [1 ,2 ]
Ryden, Lisa [3 ]
Luts, Lena [4 ]
Bendahl, Par-Ola [1 ]
Hedenfalk, Ingrid [1 ]
机构
[1] Lund Univ, Dept Oncol, S-22185 Lund, Sweden
[2] Lund Univ, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, S-22185 Lund, Sweden
[3] Lund Univ, Dept Surg, S-22185 Lund, Sweden
[4] Lund Univ, Dept Clin Pathol, S-22185 Lund, Sweden
基金
瑞典研究理事会;
关键词
Breast cancer; Basal-like; Numb; Cancer stem cell; CD44/CD24; BRCA1; ADJUVANT TAMOXIFEN; RECEPTOR; NOTCH; CARCINOMA; HYBRIDIZATION; PATIENT; TUMORS; TRIAL; LINES;
D O I
10.1007/s10549-009-0568-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Decreased expression of Numb, resulting in activation of the proto-oncogene Notch1 and reduction in the tumor suppressor p53, has been demonstrated in mammary carcinomas. The aim of this study was to investigate the relationship between Numb protein expression and clinicopathological characteristics, tumor biological subtypes and putative cancer stem cell markers in a well-characterized cohort of primary human breast cancers. Immunohistochemistry was performed on tissue microarrays of primary invasive breast tumors using a polyclonal anti-Numb primary antibody. Of the 241 tumors evaluated, 50 (21%) displayed deficient or reduced Numb immunoreactivity. Retained Numb expression was significantly correlated to estrogen (ER) and progesterone receptor (PR) positivity (P < 0.001 and P = 0.004, respectively). Interestingly, we found that a higher percentage of the tumors with deficient or reduced Numb expression belonged to the triple-negative (ER-/PR-/HER2-) subgroup compared to tumors with retained Numb expression (P = 0.004). Transcriptional profiling of a subset of these tumors linked NOTCH1 and BIRC5, both downstream targets of Numb, to the triple-negative subgroup in an inverse manner. Typically, subgroups characterized by the low expression of Numb expressed higher levels of NOTCH1 and BIRC5 (encoding survivin). We also found deficient expression of Numb in a significantly higher proportion of BRCA1 dependent tumors, which are usually triple-negative, compared to sporadic tumors. The expression of Numb in 14 breast cancer cell lines correlated similarly to their respective molecular subtypes. We further established an inverse correlation between the Numb expression levels and the CD44+/CD24- cancer stem cell phenotype (P = 0.05) in primary tumors. Finally, decreased Numb expression was associated with poorer distant disease-free survival (P = 0.01). Taken together, our results indicate that loss of Numb expression is a marker of tumor aggressiveness, potentially linked to BRCA1 status and a cancer stem cell phenotype in primary breast cancer.
引用
收藏
页码:315 / 324
页数:10
相关论文
共 26 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   Notch signaling in cancer [J].
Allenspach, EJ ;
Maillard, I ;
Aster, JC ;
Pear, WS .
CANCER BIOLOGY & THERAPY, 2002, 1 (05) :466-476
[3]   Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer -: Clinical associations and reasons for discrepancies [J].
Chebil, G ;
Bendahl, PO ;
Idvall, I ;
Fernö, M .
ACTA ONCOLOGICA, 2003, 42 (07) :719-725
[4]   NUMB controls p53 tumour suppressor activity [J].
Colaluca, Ivan N. ;
Tosoni, Daniela ;
Nuciforo, Paolo ;
Senic-Matuglia, Francesca ;
Galimberti, Viviana ;
Viale, Giuseppe ;
Pece, Salvatore ;
Di Fiore, Pier Paolo .
NATURE, 2008, 451 (7174) :76-U11
[5]   Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer [J].
Dihge, Looket ;
Bendahl, Par-Ola ;
Grabau, Dorthe ;
Isola, Jorma ;
Lovgren, Kristina ;
Ryden, Lisa ;
Ferno, Marten .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) :255-262
[6]   Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels [J].
Fernö, M ;
Stål, O ;
Baldetrop, B ;
Hatschek, T ;
Källström, AC ;
Malmström, P ;
Nordenskjöld, B ;
Rydén, S .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 59 (01) :69-76
[7]   Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma [J].
Gruvberger-Saal, Sofia K. ;
Bendahl, Paer-Ola ;
Saal, Lao H. ;
Laakso, Mervi ;
Hegardt, Cecilia ;
Eden, Patrik ;
Peterson, Carsten ;
Malmstroem, Per ;
Isola, Jorma ;
Borg, Ake ;
Fernoe, Marten .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :1987-1994
[8]   The CD44+/CD24- phenotype is enriched in basal-like breast tumors [J].
Honeth, Gabriella ;
Bendahl, Par-Ola ;
Ringner, Markus ;
Saal, Lao H. ;
Gruvberger-Saal, Sofia K. ;
Lovgren, Kristina ;
Grabau, Dorthe ;
Ferno, Marten ;
Borg, Ake ;
Hegardt, Cecilia .
BREAST CANCER RESEARCH, 2008, 10 (03)
[9]   Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization [J].
Isola, J ;
Tanner, M ;
Forsyth, A ;
Cooke, TG ;
Watters, AD ;
Bartlett, JMS .
CLINICAL CANCER RESEARCH, 2004, 10 (14) :4793-4798
[10]   Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier [J].
Johannsson, OT ;
Staff, S ;
Vallon-Christersson, J ;
Kytöla, S ;
Gudjonsson, T ;
Rennstam, K ;
Hedenfalk, IA ;
Adeyinka, A ;
Kjellén, E ;
Wennerberg, J ;
Baldetorp, B ;
Petersen, OW ;
Olsson, H ;
Oredsson, S ;
Isola, J ;
Borg, Å .
LABORATORY INVESTIGATION, 2003, 83 (03) :387-396